Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 8:28 PM ET


Company Overview of ACCU-BREAK Pharmaceuticals, Inc.

Company Overview

ACCU-BREAK Pharmaceuticals, Inc. develops and licenses pharmaceutical tablet technologies. The company offers bi-layer and tri-layer technologies, which are used to create tablets that are dividable by hand into accurate partial/smaller doses for patients to adjust their dose. Its technologies are used for single drug products, fixed and split combination drug products, standard and controlled release formulations, and incompatible drugs in human and veterinary medicines. The company has a strategic alliance agreement with Azopharma Development Group. ACCU-BREAK Pharmaceuticals, Inc. was formerly known as SoLapharm, Inc. and changed its name to ACCU-BREAK Pharmaceuticals, Inc. in April 2006....

1000 South Pine Island Road

Suite 430

Plantation, FL 33324

United States

Founded in 2001





Key Executives for ACCU-BREAK Pharmaceuticals, Inc.

President and General Counsel
Age: 59
Executive Chairman of the Board
Age: 70
Co-Founder, Vice President of Regulatory & Technical Affairs and Director
Age: 61
Executive Director
Age: 78
Compensation as of Fiscal Year 2015.

ACCU-BREAK Pharmaceuticals, Inc. Key Developments

Accu-Break Pharmaceuticals Files NDA with US FDA for Unique Anticoagulant Frequently Split Tablets Warfarin Potassium

Accu-Break Pharmaceuticals has filed its 505(b)(2) New Drug Application (NDA) for anticoagulant Warfarin Potassium with the US Food & Drug Administration (FDA). The company said the 4 mg tablet splits into exact 1 mg quarter doses, while the 5 mg tablet provides half doses. Based on IMS Data, the company believes that these two tablets address essentially all of the currently available 9 Coumadin doses. The ABP bilayer tablet technology with its backbone drug-free layer enables accurate dose adjustments of a drug that exhibits an extremely narrow therapeutic index. Along with Alembic Pharmaceuticals, the company has developed Warfarin Potassium and will manufacture the product. Both companies are seeking licensees in the US and worldwide.

Similar Private Companies By Industry

Company Name Region
Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company United States
Clinical Site Services Corporation United States
Topiderm Inc. United States
Akashi Therapeutics, Inc. United States
Bartels, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ACCU-BREAK Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at